新诊断类风湿关节炎患者引入生物制剂改善病情抗风湿药后严重感染风险:一项基于人群的间断时间序列分析
该研究基于加拿大不列颠哥伦比亚省1990—2015年行政数据,纳入1995—2007年新诊断RA患者60 226例及匹配非RA对照588 499例,分析生物制剂改善病情抗风湿药(bDMARDs)引入前后8年严重感染率趋势变化。结果显示bDMARDs引入后仅RA患者8年严重感染率随时间上升,校正后前后趋势差为1.85(P=0.001),非RA为0.12(P=0.29)。
要点
- bDMARDs引入前,RA与对照的8年严重感染率均随诊断年份推移而下降。
- bDMARDs引入后,仅RA患者8年严重感染率随时间上升,对照未上升。
- 校正后前后趋势差RA为1.85(P=0.001),非RA为0.12(P=0.29)。
核心结论
- bDMARDs引入后发病的RA患者较匹配的非RA个体严重感染风险升高。
研究设计与样本
- 基于人群的回顾性队列研究,使用加拿大不列颠哥伦比亚省1990—2015年行政数据。
- 纳入1995—2007年所有新诊断RA患者,按年龄和性别匹配无炎性关节炎的普通人群对照,并赋予其匹配RA患者的诊断日期(即索引日期)。
- RA与对照按索引日期分为季度队列,计算每个队列的8年严重感染率,并进行间断时间序列分析比较bDMARDs前(1995—2001年)与后(2003—2007年)时期的严重感染趋势。
- 共识别60 226例新诊断RA患者和588 499例对照。
主要发现
- RA患者中共识别14 245例严重感染,对照中共识别79 819例严重感染。
- 在bDMARDs前时期,RA患者和对照的8年严重感染率均随索引日历年增加而下降。
- 在bDMARDs后时期,仅RA患者的8年严重感染率随时间上升,对照未上升。
- bDMARDs前后8年严重感染率长期趋势的校正差值在RA中为1.85(P=0.001),在非RA中为0.12(P=0.29)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the impact of the introduction of biologic DMARDs (bDMARDs) on severe infections among people newly diagnosed with RA compared with non-RA individuals. METHODS: In this population-based retrospective cohort study using administrative data (from 1990-2015) for British Columbia, Canada, all incident RA patients diagnosed between 1995 and 2007 were identified. General population controls with no inflammatory arthritis were matched to RA patients based on age and gender, and were assigned the diagnosis date (i.e. index date) of the RA patients they were matched with. RA/controls were then divided into quarterly cohorts according to their index dates. The outcome of interest was all severe infections necessitating hospitalization or occurring during hospitalization after the index date. We calculated 8-year severe infection rates for each cohort and conducted interrupted time-series analyses to compare severe infection trends in RA/controls with index date during pre-bDMARDs (1995-2001) and post-bDMARDs (2003-2007) periods. RESULTS: A total of 60 226 and 588 499 incident RA/controls were identified. We identified 14 245 severe infections in RA, and 79 819 severe infections in controls. The 8-year severe infection rates decreased among RA/controls with increasing calendar year of index date in the pre-bDMARDs period, but increased over time only among RA, not controls, with index date in the post-bDMARDs period. The adjusted difference between the pre- and post-bDMARDs secular trends in 8-year severe infection rates was 1.85 (P = 0.001) in RA and 0.12 (P = 0.29) in non-RA. CONCLUSION: RA onset after bDMARDs introduction was associated with an elevated severe infection risk in RA patients compared with matched non-RA individuals.
引用
- Zhou VY, Lacaille D, Lu N, et al. Risk of severe infections after the introduction of biologic DMARDs in people with newly diagnosed rheumatoid arthritis: a population-based interrupted time-series analysis. Rheumatology (Oxford). 2023. PMID: 37014364. doi:10.1093/rheumatology/kead158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。